AstraZeneca is in midstage trials with 180 melanoma patients for a drug that hits a related target called mitogen-activated protein kinase kinase.
FORBES: Magazine Article
AstraZeneca (nyse: AZN - news - people ) is in midstage trials with 180 melanoma patients for a drug that hits a related target called mitogen-activated protein kinase kinase.
FORBES: Targeting Melanoma
应用推荐
模块上移
模块下移
不移动